Polycystic Kidney Disease - Pipeline Insight, 2025
Description
DelveInsight’s, “Polycystic Kidney Disease - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Polycystic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Polycystic Kidney Disease: Overview
Polycystic Kidney Disease (PKD) is a genetic disorder characterized by the development of multiple fluid-filled cysts in the kidneys. These cysts grow over time, leading to an enlargement of the kidneys and progressive loss of kidney function. PKD is primarily categorized into two types: autosomal dominant (ADPKD), which is the more common form and typically manifests in adulthood, and autosomal recessive (ARPKD), which is rarer and often presents symptoms in infancy or childhood. In both forms, the cysts disrupt normal kidney tissue, eventually leading to chronic kidney disease (CKD) or kidney failure.
In patients with Polycystic Kidney Disease (PKDs), the kidneys contain multiple fluid-filled cysts, although other organs may also be affected. Although PKD is inherited monogenically, it is phenotypically, genically and allelically heterogeneous. Autosomal dominant PKD (ADPKD) is the most common form of PKD and is generally an adult-onset, multisystem disorder that is characterized by gradually growing renal cysts that start to develop in utero and can originate from all areas of the kidneys, although cysts usually form in the distal regions of the nephron and the collecting duct. Progressive fibrocystic renal disease in ADPKD is often accompanied by hepatobiliary changes or other extrarenal abnormalities, such as intracranial arterial aneurysms.
To diagnose polycystic kidney disease and assess the size, number of cysts, and the health of kidney tissue, medical professionals commonly employ imaging techniques such as ultrasound, CT scans, and MRI scans. Ultrasound involves using a transducer emitting sound waves to create images of the kidneys, akin to sonar mapping. CT scans utilize X-ray beams to produce cross-sectional images, providing detailed views of the kidneys. MRI scans, employing magnetic fields and radio waves, generate high-resolution cross-sectional views, aiding in comprehensive evaluation and diagnosis of the condition.
The treatment of PKD focuses on managing symptoms and slowing the progression of kidney damage, as there is no cure. Blood pressure control, pain management, and lifestyle modifications, such as dietary changes and hydration, are key components of treatment. In recent years, new therapeutic approaches, such as the use of vasopressin receptor antagonists like tolvaptan, have shown promise in slowing cyst growth and preserving kidney function in ADPKD patients. Early diagnosis and regular monitoring are essential to improving the quality of life for individuals with PKD and delaying the onset of kidney failure.
""Polycystic Kidney Disease- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycystic Kidney Disease pipeline landscape is provided which includes the disease overview and Polycystic Kidney Disease treatment guidelines. The assessment part of the report embraces, in depth Polycystic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycystic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Polycystic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polycystic Kidney Disease Emerging Drugs
Further product details are provided in the report……..
Polycystic Kidney Disease: Therapeutic Assessment
This segment of the report provides insights about the different Polycystic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:
Polycystic Kidney Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycystic Kidney Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycystic Kidney Disease drugs.
Polycystic Kidney Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Polycystic Kidney Disease: Overview
Polycystic Kidney Disease (PKD) is a genetic disorder characterized by the development of multiple fluid-filled cysts in the kidneys. These cysts grow over time, leading to an enlargement of the kidneys and progressive loss of kidney function. PKD is primarily categorized into two types: autosomal dominant (ADPKD), which is the more common form and typically manifests in adulthood, and autosomal recessive (ARPKD), which is rarer and often presents symptoms in infancy or childhood. In both forms, the cysts disrupt normal kidney tissue, eventually leading to chronic kidney disease (CKD) or kidney failure.
In patients with Polycystic Kidney Disease (PKDs), the kidneys contain multiple fluid-filled cysts, although other organs may also be affected. Although PKD is inherited monogenically, it is phenotypically, genically and allelically heterogeneous. Autosomal dominant PKD (ADPKD) is the most common form of PKD and is generally an adult-onset, multisystem disorder that is characterized by gradually growing renal cysts that start to develop in utero and can originate from all areas of the kidneys, although cysts usually form in the distal regions of the nephron and the collecting duct. Progressive fibrocystic renal disease in ADPKD is often accompanied by hepatobiliary changes or other extrarenal abnormalities, such as intracranial arterial aneurysms.
To diagnose polycystic kidney disease and assess the size, number of cysts, and the health of kidney tissue, medical professionals commonly employ imaging techniques such as ultrasound, CT scans, and MRI scans. Ultrasound involves using a transducer emitting sound waves to create images of the kidneys, akin to sonar mapping. CT scans utilize X-ray beams to produce cross-sectional images, providing detailed views of the kidneys. MRI scans, employing magnetic fields and radio waves, generate high-resolution cross-sectional views, aiding in comprehensive evaluation and diagnosis of the condition.
The treatment of PKD focuses on managing symptoms and slowing the progression of kidney damage, as there is no cure. Blood pressure control, pain management, and lifestyle modifications, such as dietary changes and hydration, are key components of treatment. In recent years, new therapeutic approaches, such as the use of vasopressin receptor antagonists like tolvaptan, have shown promise in slowing cyst growth and preserving kidney function in ADPKD patients. Early diagnosis and regular monitoring are essential to improving the quality of life for individuals with PKD and delaying the onset of kidney failure.
""Polycystic Kidney Disease- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycystic Kidney Disease pipeline landscape is provided which includes the disease overview and Polycystic Kidney Disease treatment guidelines. The assessment part of the report embraces, in depth Polycystic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycystic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Polycystic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Polycystic Kidney Disease.
This segment of the Polycystic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Polycystic Kidney Disease Emerging Drugs
- Tamibarotene: Rege Nephro Co., Ltd.
- RGLS8429: Regulus Therapeutics Inc.
- AL1311: AceLink Therapeutics, Inc.
Further product details are provided in the report……..
Polycystic Kidney Disease: Therapeutic Assessment
This segment of the report provides insights about the different Polycystic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Polycystic Kidney Disease
- There are approx. 8+ key companies which are developing the therapies for Polycystic Kidney Disease. The companies which have their Polycystic Kidney Disease drug candidates in the most advanced stage, i.e. Phase II include, Rege Nephro Co., Ltd.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Polycystic Kidney Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycystic Kidney Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycystic Kidney Disease drugs.
Polycystic Kidney Disease Report Insights
- Polycystic Kidney Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Polycystic Kidney Disease drugs?
- How many Polycystic Kidney Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycystic Kidney Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polycystic Kidney Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Polycystic Kidney Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Rege Nephro Co., Ltd.
- Regulus Therapeutics Inc.
- Vertex Pharmaceuticals Incorporated
- AceLink Therapeutics, Inc.
- Tamibarotene
- RGLS8429
- VX-407
- AL1311
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Polycystic Kidney Disease: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Polycystic Kidney Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Tamibarotene: Rege Nephro Co., Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- RGLS8429: Regulus Therapeutics Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- AL1311: AceLink Therapeutics, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Polycystic Kidney Disease Key Companies
- Polycystic Kidney Disease Key Products
- Polycystic Kidney Disease- Unmet Needs
- Polycystic Kidney Disease- Market Drivers and Barriers
- Polycystic Kidney Disease- Future Perspectives and Conclusion
- Polycystic Kidney Disease Analyst Views
- Polycystic Kidney Disease Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
